| Title | Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Adult Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) |
|---|---|
| Disease/Condition | Sickle Cell |
| Eligibility Criteria | Click here for eligibility requirements |
| Principal Investigator | Deepa Manwani, MD |
| Contact Name | Karen Ireland |
| Contact Email | kireland@montefiore.org |
| IRB/Protocol Number | 17-02-348-01 |
| Adult Clinical Trial | Yes |
| Pediatric Clinical Trial | No |